Side effects cause 25% of patients to stop niacin treatment

March 2013
British Journal of Hospital Medicine (17508460);Mar2013, Vol. 74 Issue 3, p130
Academic Journal
The article reports a study which revealed that 25 percent of patients taking extended-release niacin with laropiprant given in addition to simvastatin to reduce the risk of cardiovascular problems, stopped their treatment due to adverse side effects such as itching, flushing and indigestion.


Related Articles

  • Nicotinic Acid: Current Status in Lipid Management and Cardiovascular Disease Prevention. Whayne, Thomas F. // Angiology;Aug2014, Vol. 65 Issue 7, p557 

    In this article, the author discusses the role of nicotinic acid in lipid management and cardiovascular disease prevention. Topics discussed include per capita use of nicotinic acid in the U.S., contribution of nicotinic acid in reduction of Low-density lipoprotein-Cholesterol (LDL-C) for...

  • Role of Colesevelam in Combination Lipid-Lowering Therapy. Jones, Michael; Nwose, Oliseyenum // American Journal of Cardiovascular Drugs;Oct2013, Vol. 13 Issue 5, p315 

    Hyperlipidemia is associated with an increased risk of cardiovascular events; reducing low-density lipoprotein cholesterol (LDL-C), the primary target for cholesterol-lowering therapy, lowers the risk for such events. Although bile acid sequestrants were the first class of drugs to show a...

  • Do patients on statins also need niacin? Jones, Kelly W. // JAAPA: Journal of the American Academy of Physician Assistants (;Jul2013, Vol. 26 Issue 7, p9 

    Niacin has been used for years to treat hypercholesterolemia, but may not be as beneficial as thought for patients at high risk of cardiovascular disease. Until further research is done, niacin should be used only in patients who do not tolerate or respond to statin therapy, and never in...

  • TAKING COENZYME Q10 WITH LIPID-LOWERING MEDS. SAFRANSKI, MARY; Sego, Sherril // Clinical Advisor;Feb2011, Vol. 14 Issue 2, p65 

    The article provides an answer to a question of whether the research support the addition of coenzyme Q10 (CoQ10) for those on lipid-lowering medication.

  • Comparative Study of Various Statin Combinations in Dyslipidaemias. Nagesh, S. V. S. D. N. A.; Sudeep, S.; Gupatha, B. M. H. R. K.; Viswasanthi, A.; Anandakumar, L.; Sreenivasulureddy, V. // Indian Journal of Public Health Research & Development;Jan-Mar2014, Vol. 5 Issue 1, p197 

    Hyperlipidaemia results from a disorder in the synthesis and degradation of plasma lipoproteins. Dyslipidaemias have genetic and other causes, and are often associated with high fat diet. The lipids that are of relevance in hyperlipidaemias are cholesterol, an essential component of cell...

  • Very-low-strength evidence suggests that combining ezetimibe or fibrate with statins is no more effective than high-dose statin monotherapy for reducing all-cause mortality. Tenenbaum, Alexander; Fisman, Enrique Z. // Evidence Based Medicine;Apr2010, Vol. 15 Issue 2, p52 

    A review is presented of the article "Systematic Review: Comparative Effectiveness and Harms of Combination Therapy and Monotherapy for Dyslipidemia" by M. Sharma et al., which appeared in a 2009 issue of the "Annals of Internal Medicine".

  • Statins in the Treatment of Hepatitis C. Vere, Cristin Constantin; Streba, Costin Teodor; Streba, Liliana; Rogoveanu, Ion // Hepatitis Monthly;Jun2012, Vol. 12 Issue 6, p369 

    The authors discuss the use of statins as a form of treatment in patients with hepatitis C virus (HCV) infection, which affects nearly 3 percent of the global population. They describe several studies that have demonstrated the efficacy of statins, a cholesterol-lowering medication in inhibiting...

  • VASCEPA (icosapentethyl): Studied in statin-treated patients with triglyceride (TG) levels ≥ 200-499 mg/dL.  // Contemporary OB/GYN;Feb2016 Supplement, p6 

    The article discusses studies on the use of Vascepa or icosapent ethyl, manufactured by Mochida Pharmaceutical Co. Ltd., in statin-treated adult patients with high triglyceride levels. Topics covered include highlights of the Japan EPA Lipid Intervention Study (JELIS) and ANCHOR trials, data...

  • Fenofibric Acid: In Combination Therapy in the Treatment of Mixed Dyslipidemia. Yang, Lily P. H.; Keating, Gillian M. // American Journal of Cardiovascular Drugs;2009, Vol. 9 Issue 6, p401 

    â–´ Fenofibric acid activates peroxisome proliferator-activated receptor a to modify fatty acid and lipid metabolism. Fenofibric acid is the first member of the fibric acid derivatives (fibrates) class approved for use as combination therapy with HMG-CoA reductase inhibitors (statins)....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics